Pruritus Therapeutics Market

Report Overview

The global pruritus therapeutics was pegged at US$ 4.22 billion in 2021 and is expected to witness a CAGR of5.1 % during the forecast period.

Market Fundamentals 

Pruritus is an itch disorder that can be brought on by a variety of illnesses, including skin conditions. Pruritus is linked to Xerosis, drug eruption, psoriasis, urticaria, arthropod bites, dermatitis herpetiformis, and mastocytosis are a few main skin disorders. Patients who suffer from pruritus have higher concentrations of ions including calcium, phosphate, and magnesium in their skin. A pruritus is a sensation that makes you want to scratch or scratch out of reflex. Modern science has demonstrated that their behavioural response mechanisms are very distinct. While pruritus causes a scratch reflex, pain causes a withdrawal reflex. Despite the fact that both pruritus and pain are unpleasant sensory sensations.

[9874953]

Market Dynamics

The rising demand for effective treatments and diagnostics to address such medical disorders, together with the increased prevalence of dermatological conditions that affect the occurrence of pruritus, are anticipated to promote market growth. It is recognized that one of the major factors driving the expansion of the pruritus therapeutic market is the rise in inorganic development strategies. Additionally, the major industry participants in the pruritus therapeutic market are gradually implementing growth tactics like alliances, local acquisitions, and mergers and acquisitions. These growth methods are projected to lead to technological advancement due to improvements in the product portfolio and shared R&D, which will further fuel market expansion.

Market Ecosystem

The global pruritus therapeutics market has been analysed by four perspectives by disease type, drug type, end user and region.

Pruritus Therapeutics Market by Disease Type

[2143224]

Based on disease type, the global pruritus therapeutics market has been segmented into allergic contact dermatitis, urticaria, atopic dermatitis, and others. During the forecast period, allergic contact dermatitis is anticipated to have a highest CAGR as it is the third most typical cause for patients to contact a dermatologist.Females are more likely than males to develop allergic contact dermatitis as a result of the rising popularity of ear, navel, and nose piercing. Between 20 and 40 percent of women suffer from nickel allergies. Contact dermatitis accounts for 95% of all reported occupational skin illnesses in the United States, where its prevalence ranges from 1.5% to 5.4%.

Pruritus Therapeutics Market by Drug Type

Based on drug type, the global pruritus therapeutics market has been segmented into corticosteroid, antihistamine, local anesthetic, counterirritant, immunosuppressant, calcineurin inhibitors, and others. The corticosteroid dominated the global pruritus therapeutics market due to the fact that corticosteroids are frequently employed as the first line of therapy. However, calcineurin inhibitors are anticipated to expand at the quickest CAGR throughout the forecast period because to its high response rate, robust pipeline of calcineurin inhibitors and availability of semi-synthetic analogues of these inhibitors.

Pruritus Therapeutics Market by End User

Based on end user, the global pruritus therapeutics market has been segmented into hospitals, clinics, and others. The hospital segment dominated the segment during forecast period due to due to government’s support and the growing number of hospitals in the region with dermatology labs will have a beneficial impact on the market's growth.

Pruritus Therapeutics Market by Region

The pruritus treatments market in the world is dominated by North America due to new products launch and the existence of supportive government initiatives are the main causes of the dominance. Additionally, it is projected that during the forecast period, the prevalence of target disorders would increase as well as the presence of climate disorders that cause pruritus in this region. Throughout the course of the anticipated period, the regional market is expected to grow as a result of the launch of new therapeutic products and the U.S. FDA's approval of generic medications for the treatment of pruritus and chronic pruritus, such as psoriasis. Growth in the regional market will also be fuelled by favourable government regulations on the treatment of pruritus. However, Asia Pacific has seen to be fastest growing region during forecast period due to the rise in atopic dermatitis and urticarial cases, as well as the existence of unmet healthcare organisation demands, are factors contributing to the market's expansion in Asia Pacific.

Competitive Landscape

Some of the prominent market players in the global pruritus therapeutics market include 

• Cara Therapeutics
• AbbVie, Inc.
• Sanofi Aventis
• UCB Pharma
• Pfizer, Inc. 
• Amgen, Inc. 
• Actavis Plc
• GlaxoSmithKline. PLC
• Galderma 
• Chongqing Huapont Pharm Co. Ltd. 
• Bayer AG
• UCB Pharma
• LEO Pharma
• EPI Health, LLC
• Galderma Laboratories, LP. 
• Novartis AG 
• Mc2 Therapeutics A/S

Strategic Developments

• In June 2020, Cara Therapeutics, a clinical-stage biopharmaceutical company, announced the successful conclusion of its Phase-II dose-ranging oral Korsuva trial for moderate to severe chronic kidney disease-associated pruritus. This company is anticipated to fuel the competitiveness in the market during the forecast period thanks to its novel and proprietary product class.
• In February 2021, Global biopharmaceutical company Almirall S.A. and MC2 Therapeutics, a pharmaceutical company in the commercial stage that produces topical therapies for autoimmune and chronic inflammatory conditions, have confirmed that MC2 Therapeutics has given Almirall exclusive European rights to market WYNZORA Cream for the treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults.

Frequently Asked Questions About This Report